Recent researches have shown that PD-L1 plays an important role in immune escape of ovarian cancer cells, and the clinical trial results of targeted immunotherapy for PD-L1 in ovarian cancer patients have not been as dramatic as those in melanoma or non-small cell lung cancer [30, 31]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.